Opus Genetics Inc (IRD) FinancialsIRDFinancialOpus Genetics Inc

Evaluating the bottom line, Opus Genetics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2182.78%, while the net margin is -1072.58%. These profitability ratios, combined with a Return on Equity (ROE) of -4796.52%, provide a clear picture of how effectively IRD converts its operational activities into shareholder value.

In the context of the broader market, IRD competes directly with industry leaders such as EBS and PRQR. With a market capitalization of $300.34M, it holds a significant position in the sector. When comparing efficiency, IRD's gross margin of 100.00% stands against EBS's 58.56% and PRQR's 100.00%. Such benchmarking helps identify whether Opus Genetics Inc is trading at a premium or discount relative to its financial performance.

Opus Genetics has shown a significant increase in stock performance with a year-to-date change of +74.06% and a one-year change of +200.00%. However, the company has been consistently reporting negative net income, with the latest figure at -65,535,000 USD for Q1 2026.